Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Clinical trial NCT07469956 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07469956
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2028-01-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.